Abstract 5615: ALRN-0192519 is a potent and selective EGFR L858R mutation inhibitor that demonstrates anti-cancer activity in preclinical cancer models as monotherapy or in combination with osimertinib
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Jiaqi Liang, Yezhen Zhang, Lisha Xie, Jihong Chen, Xipan Liu, Wenheng Liang, Tingru Zhou, Xiaobin Zhang, Tao Ji, David Pirovich, Xiang Zhai, Yipin Lu, Ming Yu, John Campbell, Fang Li, Yaoyu Chen, Lina Gu
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409631395